Compare Health Care Select Sector SPDR Fund (XLV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Health Care Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Health Care Select Sector SPDR Fund trades at $170.79 (market cap $43.48B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Health Care Select Sector SPDR Fund is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Health Care Select Sector SPDR Fund for 100 Days and Zoetis Inc for 70 Days on average.
| XLV | ZTS | |
|---|---|---|
Market Cap | $43.48B | $30.20B |
Volume | 11,121,431 | 6,175,327 |
52-Week High | $175.68 | $147.53 |
52-Week Low | $141.95 | $69.09 |
Typical Hold Time | 100 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLV trades at $170.81, up 1.18% with a bearish technical signal from moving averages. The ETF's low 0.08% expense ratio and healthcare sector diversification provide defensive positioning amid market volatility. Recent options activity shows increased put volume, indicating some investor caution despite healthcare's traditional defensive characteristics during economic uncertainty.
Healthcare sector ETFs like XLV offer defensive exposure with potential upside from demographic trends and innovation. Key risks include political volatility around healthcare policy and concentration in large-cap US stocks. The ETF's cost efficiency and sector positioning make it attractive for long-term investors seeking healthcare exposure.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
